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Prenatal examination plays an important role in present medical diagnosis. It provides information on
fetal health status as well as the diagnosis of fetal treatment feasibility. The diagnosis can provide peace
of mind for the perspective mother. Timely pregnancy termination diagnosis can also be determined if
required. Amniocentesis and chorionic villus sampling are two widely used invasive prenatal diagnostic
procedures. To obtain complete fetal genetic information and avoid endangering the fetus, noninvasive
prenatal diagnosis has become the vital goal of prenatal diagnosis. However, the development of a high-
efﬁciency separation technology is required to obtain the scarce fetal cells from maternal circulation. In
recent years, the rapid development of microﬂuidic systems has provided an effective method for fetal
cell separation. Advantages such as rapid analysis of small samples, low cost, and various designs, greatly
enhance the efﬁciency and convenience of using microﬂuidic systems for cell separation. In addition,
microﬂuidic disks can be fully automated for high throughput of rare cell selection from blood samples.
Therefore, the development of microﬂuidic applications in noninvasive prenatal diagnosis is unlimited.
Copyright © 2015, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Prenatal diagnosis is an importantmedical technology for nearly
two centuries. The procedure can notify parents of hereditary dis-
eases in the fetus such as Down syndrome, sickle cell anemia,
Edwards's syndrome, cystic ﬁbrosis, and Duchenne muscular dys-
trophy. These diseases may cause neonate stunted growth, intel-
lectual disability, physical disability, and death. To date, expecting
parents can select various methods to conﬁrm fetal health. How-
ever, different diagnosis methods may be presented with different
levels of risks, where invasive prenatal diagnosis procedures may
induce miscarriage risks. Therefore, the development of safe and
highly valuable prenatal diagnostic techniques is greatly sought
after for scientists around the world.
The ﬁrst prenatal diagnosis can be traced back to as early as the
20th century, after Wilhelm R€ontgen's [1] discovery of X-rays.
Although X-rays can be utilized to observe fetus appearance, itryngology and Biotechnology
ing University, Number 155,
edu.tw (T.-P. Lee).
bstetrics & Gynecology. Publishedprovides no genetic diagnosis. In 1966, Steele and Breg [2] separated
fetal chromosomes from amniotic ﬂuid for chromosome analysis
which has laid the foundation of amniocentesis inmodernmedicine.
Later, an Italianbiologist, Simoniet al [3], performedtheﬁrst trimester
chorionic villus sampling (CVS) and risk assessment to validate this
method as a reliable prenatal diagnosis tool [3,4]. These twomethods
are regarded as a model for prenatal diagnosis; however, their inva-
sivenessmay lead to a risk ofmiscarriage. Due to the potential risks of
invasive prenatal genetic diagnosis, different noninvasive prenatal
diagnosis (NIPD) techniques are actively being developed.Invasive prenatal diagnosis
Although invasive prenatal diagnosis is dangerous, there exists
no effective replacement among today's technologies. Table 1 in-
dicates the most direct methods of siphoning fetal samples from
the mother and their associated risk of miscarriage [5e9].Amniocentesis
Amniocentesis was used to treat pregnant women with poly-
hydramnios in 1880. In 1966, American physicians Steele and Bregby Elsevier Taiwan LLC. All rights reserved.
Table 1
Comparison of invasive prenatal diagnosis.
Execution
time (wk)
Sampling location Diagnosis Risk of
miscarriage (%)
Refs
Chorionic villous sampling 10e12 Chorionic villus Chromosomal abnormalities 0.5e2 [5]
Amniocentesis 14e16 Amniotic sac Chromosomal abnormalities/neural tube defects 0.06e1.3 [6,7]
Fetal blood sampling 17 Fetal umbilical cord Chromosomal abnormalities/metabolic disorders/fetal infections 2e3 [8,9]
FISH ¼ ﬂuorescence in situ hybridization; PCR ¼ polymerase chain reaction.
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analysis. Presently, it is the most widely used invasive prenatal
diagnosis because of its high accuracy and low risk characteristics.
Previous research has suggested that spontaneous abortion per-
centage after amniocentesis is 1.7% [10], which was slightly higher
than the control group that underwent only ultrasonic examina-
tions. The report in 2000 also suggested that the fetus miscarriage
risk of amniocentesis is ~0.6e0.68% [11]. This method is applicable
for women at 16e18 weeks of pregnancy, and ~200e300 mL of
amniotic ﬂuid in the uterus of pregnant women is required. Am-
niotic ﬂuid contains ~2e3  105 cells per 10 mL, and these cells are
produced by fetal movements in the amniotic sac due to swal-
lowing, urination, and physical movements [12]. Amniocentesis is
useful for the diagnoses of many single-gene diseases and
congenital defects such as Down syndrome, thalassemia, Adreno-
leukodystrophy, and Huntington's Disease.
Chorionic villous sampling
The advantage of CVS is that it is suitable for early screening for
women at around 10e13 weeks of pregnancy and in special cases it
can be performed as early as 8 weeks [13]. This approach extracts
tissue and fetal placental chorionic cells transcervically or trans-
abdominally, where the transabdominal method has been
conﬁrmed to be safer than the transcervical method in a previous
report [14]. The miscarriage risk of CVS is higher than amniocen-
tesis, which is ~0.5e2%. The fetal diseases that can be identiﬁed by
CVS are similar to those of the amniocentesis, which include
chromosomal abnormalities and genetic defects [5].
Percutaneous umbilical cord blood sampling
Cordocentesis, also known as percutaneous umbilical cord
blood sampling (PUBS), draws blood samples directly from the fetal
umbilical vein with a sampling needle. This method is suitable for
women at the second trimester pregnancy stage, generally per-
formed after 17 weeks of pregnancy [15]. The late sampling time of
PUB than amniocentesis and CVS is because the early fetal umbilical
vein is fragile and not suitable for puncture. Studies that investi-
gated umbilical cord puncture procedure and fetal damage foundTable 2
Comparison of noninvasive prenatal testing.
Execution
time (wk)
Target Diagnosis
Ultrasonography <20 (1) Nuchal translucency
(2) Nose bone
Down's sy
Deformity
Triple test 16 (1) a-fetoprotein
(2) Oestriol
(3) hCG
Down's sy
Neural tub
Cell-free fetal DNA (mRNA)
in maternal blood
>12 (1) Fetal mRNA
(2) Fetal DNA
Single-gen
Aneuploid
Fetal cell in maternal blood 4e14 (1) Fetal lymphocytes
(2) Trophoblasts
(3) Nucleated red blood cells
The diseas
detected b
or FISH
FISH ¼ ﬂuorescence in situ hybridization; PCR ¼ polymerase chain reaction.no obvious pathological symptoms a week after PUBS [16]. Such
direct sampling method has certain risks associated with gesta-
tional age, operating procedures, and sampling frequency of needle
piercing, with different outcomes [8]. A statistical analysis has
indicated that PUBS causes ~2e3% of miscarriages [9]. However,
PUBS can be used to diagnose fetal chromosomal abnormalities,
infections, andmetabolic disorders that cannot be determined with
CVS or amniocentesis.
NIPT
Currently, many scientists have been developing NIPT tech-
niques for collecting fetal samples in order to reduce the risk of
miscarriage from invasive procedures. Table 2 summarizes each
technique and its disadvantages [17e28].
Ultrasonography
Ultrasonography is generally considered as a safe method of
image rendering. It is one of the most common NIPT technologies,
where images are formed when the echoes of ultrasound that
penetrated the uterus tissue is received. The sound waves are re-
ﬂected to the receiving probe with various interfaces, and after
concussion, the signals are transformed to electrical signals to
render two-dimensional, three-dimensional, or higher images. Ul-
trasound is often used for examining fetal congenital disability or
abnormal development, by observing fetus nuchal translucency
and nose bone development, which can predict the possibility of a
fetus suffering from Down syndrome. However, in clinical practice,
Down syndrome diagnosed with ultrasonography has a high false
positives rate of ~5% [17]. Although ultrasonography examination
cannot detect most of the inherited diseases or genetic defects, it is
still an indispensable NIPT tool.
First and second trimester screening
Second trimester maternal serum screening includes double,
triple, and quadruple tests. It is one of the most commonly chosen
examinations. This method determines speciﬁc protein concen-
trations in maternal serum to calculate the likelihood and riskDetection rate for
Down's syndrome (%)
Disadvantage Ref.
ndrome 80e90 High false positive (4.5e6.0%) [17e19]
ndrome
e defects
60e70 No deﬁnitive diagnosis [20,21]
e disorders
y
>99 Large sample
Cost effectiveness
[22e25]
e can be
y PCR
75 Very rare [26e28]
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dicators such as alpha-fetoprotein, oestriol, and human chorionic
gonadotropin [29,30]. The execution time is during the second
trimester of pregnancy, which is equivalent to ~15e20 weeks. The
attractive advantage of maternal serum screening is that the serum
is taken directly from the mother, with no invasion into the uterus.
However, previous studies have indicated that this method of
testing for Down syndrome is associated with a 5% false positive
rate and the sensitivity is ~57e60% [31,32]. The current most
effective noninvasive screening for trisomy 21 is a combination of
maternal age, measurement of fetal nuchal translucency, maternal
serum free b-human chorionic gonadotropin, and pregnancy-
associated plasma protein-A concentration at 11þ0 weeks to 13þ6
weeks of gestation. This combinatory method provided around 90%
detection rate of trisomy 21 with the false-positive rate of 5% [33].
In different strategies, all of the high risk assessments are recom-
mended to be performed in combination with amniocentesis or
CVS for deﬁnitive conﬁrmation.
Cell-free fetal DNA/mRNA in maternal blood
In 1996, two teams observed cell-free DNA in patient serums for
small-cell lung cancer and head and neck cancer [34,35]. The
identiﬁcation of cell-free DNA in serum has prompted the devel-
opment of other related diagnostic technologies. Lo et al [36], was
successful in identifying a male fetus cell-free DNA from the
mother's serum and plasma. Three years later, fetus cell-free mRNA
was also found from the mother's plasma [37].
A previous study has used real-time polymerase chain reaction
(PCR) to quantify the cell-free DNA found in maternal plasma, and
observed 3e6% of Y-chromosomal sequences [38]. This result
suggests that maternal plasma contains a certain amount of fetal
cell-free DNA for prenatal analysis. Generally cell-free DNA is
commonly used for sex determination, fetal Rhesus D blood group
identiﬁcation, and the diagnosis of single-gene disorders such as
achondroplasia and b-thalassemia [39e42]. However, due to the
fragmented nature of cell-free DNA, the identiﬁcation of fetus DNA
is often difﬁcult, where the distinctions are oftenmade by fetal DNA
markers such as male fetus Y chromosomal markers, single-
nucleotide polymorphisms, and unique fetal DNA methylation
markers [43]. Because of fragment information, cell-free DNA
analysis has limitations for identifying fetal aneuploidy diseases
such as Down syndrome, Edward's syndrome, and Patau syndrome
[38,44]. Next generation sequencing can sequence a large amount
of DNA sequences in a short time with upgraded computing speed
and decoding algorithms. With massive parallel sequencing and
powerful bioinformatics processing, maternal fetal cell-free DNA
diagnosis of fetal aneuploidy has been demonstrated recently [45],
with a 99% detection rate of Down syndrome and false positive
rates of <1% [46e49]. In August 2011, a technology called Nonin-
vasive Fetal Trisomy NIPD of Down syndromewasmade available in
a private prenatal diagnosis center in Hong Kong [45]. This method
uses GC-correlation methodology with massively parallel
sequencing for large-scale sequencing of maternal serum cell-free
DNA [50]. The DNA fragments were obtained through computer
analysis of sequencing results, and the analysis of aneuploidy was
performed by comparing the DNA fragments to those found with
normal levels in pregnant women in the control sample pool [23].
However, the acceptance of such exorbitant novel technology from
the general public is very low.
Fetal cell in maternal blood
The ﬁrst observation of fetal cells in maternal blood circulation
was made by Christian Georg Schmorl, a German pathologist, in1893. He had found multi-nucleated syncytial trophoblasts in lung
tissue of a pregnant woman that died from eclampsia [51]. This
discovery indicated that fetal cells are drawn into the mother's
body through some mechanisms and thereby enabling NIPD by
separation of fetal cells from maternal blood. Compared with the
maternal fetal free DNA/mRNA, maternal circulating fetal cells have
complete genetic information in their nucleus or cytoplasm that
can be useful for advanced complex genetic diagnosis. This is
especially useful when identifying fetal genetic defects that the
mother or father also possess, since the fetal cell is not easily
mistaken as a parent natively cell. However, the frequency of fetal
cells is very low. Therefore, effective isolation techniques for fetal
cells have been the subject of constant research and development.
The types of fetal cells inmaternal blood can be broadly classiﬁed as
trophoblasts, fetal lymphocytes, fetal nucleated red blood cells
(fnRBCs), and hematopoietic stem cells (HMCs) [52]. Due to the
different characteristics of each type of cell, these cells may have a
different difﬁculty of separation and can affect the accuracy of the
analyses.
Trophoblasts
Trophoblasts have been isolated as a target in earlier cell fetus
research with speciﬁc antitrophoblast antibody H315 [53e55].
However, a later report has reported that this antibody is not suf-
ﬁcient to separate trophoblasts for prenatal diagnosis [56].
Furthermore, trophoblasts should not appear in normal pregnant
women. Some reports have indicated that ~1% of placental cells
with placental mosaicism can lead to discrepancies in the true state
of cell nucleus type [57,58], which can greatly affect the accuracy of
trophoblast based diagnosis. Therefore, NIDP based on trophoblasts
is limited.
Fetal lymphocytes
Previous studies have found cells with XY chromosomes in
pregnant women from conceived male fetuses [59,60]. These cells
are fetal lymphocytes that have crossed the placenta into maternal
circulation. Some groups have used fetal lymphocytes for fetal sex
prediction [59,61], and have indicated by microscopic observation
that one in every 1000e5000 mother lymphocytes is a Y-chromo-
some lymphocyte [62]. In addition, fetal lymphocytes can be
ampliﬁed with in vitro culture [43], where the rare cell population
can be ampliﬁed for additional analysis. The fatal ﬂaw of using fetal
lymphocytes for NIPT is that fetal cells can retain in the mother for
27 years [63]. Therefore, the test results are not reliable for second
pregnancies.
HMCs
Fetal cells are very rare; therefore many researchers have
increased the number of target cells to include other potentially
useful fetal materials. In recent years, some groups included CD34þ
fetal stem cells to the target list [64]. CD34þ HMCs have the ability
for in vitro culture like fetal lymphocytes, however, maternal and
fetal CD34þ HMCs are not easily distinguishable. The HMC culture,
while easily enlarged, the separation of fetal cell frommaternal cell
contamination is an important issue. It is also worth noting that
residual CD34þ HMCs are also found in women after pregnancy
[52].
FnRBCs
The NIPD suitable target cells should have several properties
such as a short half-life, appears in the early stages of pregnancy,
and have speciﬁc cell markers. The fnRBCs are a good candidate
with all three properties [52], which are also the most studied and
isolated fetal cells from maternal blood [64e71]. The biggest
drawback of this type of cell is that they are very rare and some of
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have pointed out that each milliliter of maternal blood contain one
to two fnRBCs [67,68], while another group has also reported
hundreds of fnRBCs/mm of maternal blood [65]. The fnRBCs are
approximately between 9mm and 13 mm in diameter, which is
bigger than adult RBCs (6e8 mm) [73] and more similar to white
blood cells (8e15 mm). The density of fnRBCs ranges between
1.077 g/mL and 1.130 g/mL [74], similar to those of the adult RBCs
(1.090e1.110 g/mL). Nucleated RBCs are RBCs that have not
denucleated or are mid-erythroblasts in erythropoiesis, where the
erythroblast discharges the cell nuclear and becomes a reticulocyte
before entering into circulation. The discharged cell nucleus is
called a pyrenocyte and are scavenged by microphages [75].
The inter- and extracellular cell markers of fnRBCs change
following the development process. For example, burst-forming
unit erythroid during early hematopoiesis express CD71 in bone
marrow, but CD71 disappears when cells differentiate into mature
RBCs. Hemoglobin appears later, gradually formed in the late
erythroblast. CD45 has not been observed in full development
process [76].
The biggest difference between fnRBCs and adult RBCs is the
hemoglobin structure. Generally, a globin chain constructs of he-
moglobin tetramers in RBCs and nRBCs changes at different stages
of fetal development. The currently known fetal hemoglobin con-
tains z2ε2, z2g2, a2ε2, and a2g2 [73], unlike adult RBCs tetramers of
a2b2. The hemoglobin in fetal hematopoiesis is also called em-
bryonic hemoglobin, and z and ε globin chain will be replaced by
adult hemoglobin at ~9e18 weeks of gestation [77,78]. Hemato-
poiesis remains after the fetus's birth, and is transferred to the bone
marrow. The g globin chain will not completely disappear, but the
vast majority of hemoglobin tetramers will be ofa2b2 [77,78]
Therefore, ε and g globin chain can be used to distinguish be-
tween maternal nRBCs and fnRBCs in maternal blood; however, g
globin chain may appear in general adult patients with beta-
thalassemia [79], and ε globin chain disappears in early preg-
nancy. These speciﬁc markers are used by many researchers for
isolating fetal cells [79e81].
FnRBCs separation from maternal blood
There are many methods such as a magnetic-activated cell
sorting (MACS), charge ﬂow separation, ﬂuorescence-activated cell
sorting (FACS), density gradient centrifugation (DGC), and immu-
nomagnetic beads for separating fetal cells from maternal blood.
The purity and recovery rate are different for each of the methods.
For most experiments, a combination of different separationTable 3
Isolation of fetal cells.
Group Year Target cells Method
Ponnusamy et al 2008 FNRBCs Percoll 1118 DGC/MACS Depletio
positive selection/selection lysis
Samura et al 2000 NRBCs Histopaque 1119 or 1090 DGC/M
CD45/ﬂow sorting g-Hbþ
Ikeya et al 2005 NRBCs Histopaque 1095/Lectin method
Prieto et al 2001 Fetal NRBCs Double DGC 1.077 & 1.107/MAC
D'Souza et al 2009 Fetal NRBCs Percoll DGC/FACS (CD71þ or GPA
Calabrese et al 2012 NRBCs
CD34þ cells
Ficoll 1083 DGC/Dual-probe FISH
or CD34þ/i-antigenþ)
Pongsritasana et al 2006 FNRBCs Ficoll DGC/FACS or MACS (CD45-
Jeon et al 2010 Fetal NRBCs Double Percoll DGC 1.077 & 1.11
Bischoff et al 2003 Progenitor cells RosetteSep progenitor enrichme
depletion
DGC ¼ density gradient centrifugation; FNRBC ¼ fetal nucleated red blood cells; MACS ¼technology is often used to ensure sample purity. However, the
increase in separation concatenation may decrease the recovery
rate. However, poor separation methods will lead to low sample
purity. Therefore, the design for optimal separation for the exper-
iments will be the most important part of cell separation. Table 3
summarizes the performance of each isolation technique of fetal
cells [26,64,65,68e70,82e84].
In fnRBCs separation, most research groups separate peripheral
blood mononuclear cell (PBMC) from maternal blood, and remove
RBCs using DGC [64,65,67,69,85]. The DGC separation buffer con-
tains Ficoll, Percoll, and Histopaque (Sigma). Histopaque is Ficoll,
with the addition of sodium diatrizoate products that enhance
stratiﬁcation in blood samples. The DGC separation buffers are
divided into different densities, some of the commonly densities
are 1.077 g/mL, 1.083 g/mL, and 1.119 g/mL. Previous studies have
isolated fnRBCs from Ficoll DGC separated RBCs [64,67]. Another
study has also determined that buffers with a higher density
(1.119 g/mL) are better for isolating RBCs than low density buffers
(1.090 g/mL) [68]. In addition, cell loss in Ficoll DGC and Percoll DGC
with 1.7  106 CD45-mononuclear cells, observed after imple-
mentation of Ficoll DGC or Percoll DGC, the ratio of loss was 14.6%
and 41.2%, respectively [86]. These results indicate that different
DGC separation buffers in different cell types will have different
recovery rates.
After extracting PBMC from maternal blood using DGC, the
fnRBCs groups are further separated with fetal speciﬁc cell surface
markers. The most common screening methods are MACS, FACS,
and immunomagnetic beads. The removal the CD45þ cells prior to
separation can effectively enhance the results of all puriﬁcation
techniques [87]. The CD45 cell population can be used as fnRBCs
speciﬁc cell marker for positive selection. CD71 is the most com-
mon fnRBCs surface marker [64,88,89] that is also known as
transferrin receptor or p90. It is the ﬁrst cell marker to be used to
separate fnRBCs [90]. There are also some groups that have chosen
glycophorin A as themain cell marker for separation [69]. However,
glycophorin A may appear on mature RBCs [76], so unless the
previous step has the ability to remove the RBC cleanly, otherwise it
will seriously affect the purity of the result. The fnRBCs can also be
selected by i-antigen or g-hemoglobin [64,68]. The i-antigen is
originally expressed on the fnRBCs, which is gradually replaced by
I-antigen after birth [91]. However, adult RBCs will still express a
small amount of i-antigen [92], which may interfere with the
separation results. In terms of speciﬁcity, the fetal speciﬁc hemo-
globin is the best choice for separation. However, hemoglobin is an
intracellular cell marker where immunoﬂuorescence and cell
permeability and ﬁxation will lead to cell loss. In addition, usingEfﬁciency Refs
n CD45/GPA 3.0 cells/20mL blood (conﬁrmed with ε-Hb) [69]
ACS Depletion 10.67e21.91 cells/17 mL blood [68]
89.4 ± 92.6 cells/10mL blood (conﬁrmed
with MGG and HbF)
[82]
S selection 194.6 cells/8.5mL blood [70]
þ, CD45-, HbFþ) 31e499 cells/7mL bloods [65]
(CD71þ/i-antigenþ 71000 cells/25mL blood [64]
/CD71þ/CD235Aþ) 1.7e2.2  106 in MNCs [26]
9/MACS CD71 selection 9.85e14.88 cells/10mL blood [83]
nt cocktail/CD45 6200 cells/20e30mL blood [84]
magnetic activated cell sorting; NRBC ¼ nucleated red blood cells.
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must consider if the beads are taken into the cells or conjugated
through the primary antibody. Therefore, using intracellular cell
marker for fnRBCs separation will encounter more difﬁculties.
Most of the group's fnRBCs separation countermeasures were to
ﬁrst remove most of the RBCs by DGC. The PBMC collected from
interphase after DGC and CD45þ cell separation were then sub-
jected to MACS, FACS, immunomagnetic beads, or other selection
technologies. However, novel separation procedures are still being
developed. For example, the direct use of the lectin method after
DGC crawl fnRBCs or size-base separation by using microﬂuidic
chips [67,71,82]. Although the present method for fnRBCs separa-
tion has many options, the investigation of an optimum separation
process is being investigated by scientists around the world.
The isolation techniques of fnRBCs using microﬂuidic
With the constant development of micro- and nano-technology,
novel process technology can be combined with biological mate-
rials into a tiny chip. This portable biochip, also called Lab-on-a-
chip or micro total analysis systems, are widely used in cell sepa-
ration technologies such as microﬂuidic, size-dependent hydrody-
namic ﬁltration, magnetic, and electrophoresis [93]. Microﬂuidic
has been proven to effectively combine a variety of analytical sys-
tems that operate with a small amount of the sample for ease of
sampling [94]. Microﬂuidic or microﬂuidic disk, with respect to
ﬂow cytometry, express higher sensitivity for rare cell separation
[95]. The advantage of using microﬂuidic for cell separation include
speciﬁc chip ﬂow channel design for a single cell, automated
experimental processes, high throughput, and reduced use of re-
agents and generated chemical wastes [96].
Microﬂuidic can separate fetal cells by physical properties such
as size, deformability, electric, and optical properties. Antibody
screening with speciﬁc cell markers can also be used with the
system [96]. A previous study has used DGC followed by size-
speciﬁc microﬂuidic chip and cell deformation to separate
fnRBCs, in which it showed an average separation of 1.2 fetal cells/
mm of maternal blood [67]. Another group has also used DGC, size-
based microﬂuidic system, followed by magnetic beads for the
selection of hemoglobin, which collected 274.38 nRBCs/mm of
maternal blood [71]. These results indicated that the design of the
microﬂuidic system can greatly affect the efﬁciency and recovery
rate of separation. Currently, most practices use DGC followed by
traditional methods to remove RBCs before microﬂuidic chip cell
separation. However, DGC functional microﬂuidic disk has gained
much attention in recent years. The microﬂuidic disk not only
improved process automation, it was also demonstrated to separate
rare cells from blood [95,97]. Despite this, there exists few reports
that have utilized microﬂuidic disks for fetal cell separation from
maternal blood. The further development of such devices still
shows much promise.
Operation after fnRBCs separation
The use of fnRBCs, resulting from different separation tech-
niques is an important topic. Known fetus common hereditary
diseases such as aneuploidy, chromosome defects, and genetic
defects are diagnosed by the appearance of chromosomes, gene
sequencing, PCR, multiplex ligation-dependent probe ampliﬁca-
tion, and ﬂuorescence in situ hybridization (FISH). However, the
resulting fetal cell isolation is often contaminated by maternal cells
(background interference). Therefore, the sensitivity of the
methods for the subsequent genetic analysis is very important. A
previous study has demonstrated the use of highly sensitive FISH
for the observation of triploid chromosome 21, 13, and 18, wherethe sensitivity is up to 0.01% and the accuracy is >98% [85]. Tech-
niques such as PCR and other methods may be more difﬁcult than
FISH for the observation of hereditary diseases under large back-
ground interference. Even after the ampliﬁcation of speciﬁc gene
fragments, the fetus signals are still easily obscured by the signals
from maternal background cells. Therefore, samples with low pu-
rity are more suitable to use FISH for the direct calibration and
observation of speciﬁc cells, which can avoid large interferences
from the maternal background cells.
If diagnostics by PCR is required, with sequencing or other
analogous molecular biology techniques, it is necessary to increase
sample purity. Antibody and immunomagnetic based separation
have a certain degree of limitation for improving purity, because
with the use of antibodies it is difﬁcult to avoid nonspeciﬁc cali-
bration and adhesion. Therefore, micromanipulation may be the
most effective way for improving sample purity [52]. Microma-
nipulation relies on the operator to identify the cell types, and a
single cell is isolated from a large background of cells. Many mo-
lecular biology techniques are sufﬁcient to support the operation of
a single cell. For example, single cell PCR requires only one of the
target cells for gene ampliﬁcation. Capillary electrophoresis and
short tandem repeat fragment analysis can then be used to
distinguish the single cell from mother or fetus [64]. Many studies
have also reported that mothers with abnormal fetuses have
increased amount of maternal blood nRBC [24,98]. The number of
normal maternal nRBCs is between one to 12 cells, however, a
mother with a fetus suffering from beta-thalassemia will have
increased nRBCs of about 22e158 cells; and a mother with
abnormal ultrasonography fetal diagnosis also exhibits more nRBCs
[98]. The reasons for this phenomenon is not yet clear, and perhaps,
in the future, can be used as a noninvasive diagnostic indicator for
the risk of fetal chromosomal abnormalities.
Conclusion and perspectives
Using NIPD for prenatal diagnosis of aneuploidy and genetic
disease, where risk-free collection of fetal samples has become the
focus of recent prenatal diagnosis developments. Although cell free
DNA in maternal blood has been widely used and accepted in
clinical examinations, it relies heavily on new sequencing tech-
nologies that are relatively expensive. In addition, cell free DNA for
the diagnosis of aneuploid and maternally inherited diseases is
difﬁcult. Therefore, fetal cells in maternal blood are an ideal solu-
tion for this limitation. With the progressive advancement in sep-
aration technology, microﬂuidic cell separation has become more
simple and common. The microﬂuidic system is easily operated
through automation, and requires only a trace amount of sample,
which in term saves human resources and reduces costs. Further-
more, the subsequent processing of fetal cells is not limited to large
fragment gene sequencing; it is able to support various molecular
biology techniques for the ease of analysis.
Conﬂicts of interest
The authors have no conﬂicts of interest relevant to this article.
References
[1] R€ontgen WC. On a new kind of rays. Science 1896;3:227e31.
[2] Steele MW, Breg Jr WR. Chromosome analysis of human amniotic-ﬂuid cells.
Lancet 1966;1:383e5.
[3] Simoni G, Tibiletti MG, Dalpra L, Ferrari M, Brambati B. Routine chromosome
analysis on fetal blood microaliquots obtained at fetoscopy. Prenat Diagn
1983;3:203e8.
[4] Kuliev AM, Modell B, Jackson L, Simpson JL, Brambati B, Rhoads G, et al. Risk
evaluation of CVS. Prenatal Diagn 1993;13:197e209.
W.-L. Cheng et al. / Taiwanese Journal of Obstetrics & Gynecology 54 (2015) 343e349348[5] Tabor A, Vestergaard CH, Lidegaard O. Fetal loss rate after chorionic villus
sampling and amniocentesis: an 11-year national registry study. Ultrasound
Obstet Gynecol 2009;34:19e24.
[6] Eddleman KA, Malone FD, Sullivan L, Dukes K, Berkowitz RL, Kharbutli Y, et al.
Pregnancy loss rates after midtrimester amniocentesis. Obstet Gynecol
2006;108:1067e72.
[7] Odibo AO, Gray DL, Dicke JM, Stamilio DM, Macones GA, Crane JP. Revisiting
the fetal loss rate after second-trimester genetic amniocentesis: a single
center's 16-year experience. Obstet Gynecol 2008;111:589e95.
[8] Buscaglia M, Ghisoni L, Bellotti M, Ferrazzi E, Levi-Setti P, Marconi AM, et al.
Percutaneous umbilical blood sampling: indication changes and procedure
loss rate in a nine years' experience. Fetal Diagn Ther 1996;11:106e13.
[9] Antsaklis A, Daskalakis G, Papantoniou N, Michalas S. Fetal blood sam-
plingeindication-related losses. Prenatal Diagn 1998;18:934e40.
[10] Tabor A, Philip J, Madsen M, Bang J, Obel EB, Norgaard-Pedersen B. Rando-
mised controlled trial of genetic amniocentesis in 4606 low-risk women.
Lancet 1986;1:1287e93.
[11] Wilson RD, Langlois S, Johnson JA, Society of Obstetricians and Gynaecologists
of Canada. Mid-trimester amniocentesis fetal loss rate. J Obstet Gynaecol Can
2007;29:586e95.
[12] Weise W, Gabriel D, Tanner B. Growth behavior of amnion cell cultures.
Zentralbl Allg Pathol 1984;129:499e505.
[13] Wapner RJ, Evans MI, Davis G, Weinblatt V, Moyer S, Krivchenia EL, et al.
Procedural risks versus theology: chorionic villus sampling for Orthodox Jews
at less than 8 weeks' gestation. Am J Obstet Gynecol 2002;186:1133e6.
[14] Jackson LG, Zachary JM, Fowler SE, Desnick RJ, Golbus MS, Ledbetter DH, et al.
A randomized comparison of transcervical and transabdominal chorionic-
villus sampling. The U.S. National Institute of Child Health and Human
Development Chorionic-Villus Sampling and Amniocentesis Study Group.
New Engl J Med 1992;327:594e8.
[15] Vantanasiri C, Kanokpongsakdi S, Manassakorn J, Thitadilok W,
Swasdimongkol S, Tontisirin P, et al. Percutaneous umbilical cord blood
sampling. J Med Assoc Thai 1989;72:541e4.
[16] Jauniaux E, Donner C, Simon P, Vanesse M, Hustin J, Rodesch F. Pathologic
aspects of the umbilical cord after percutaneous umbilical blood sampling.
Obstet Gynecol 1989;73:215e8.
[17] Muller F, Benattar C, Audibert F, Roussel N, Dreux S, Cuckle H. First-trimester
screening for Down syndrome in France combining fetal nuchal translucency
measurement and biochemical markers. Prenatal Diagn 2003;23:833e6.
[18] Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH. UK multicentre project
on assessment of risk of trisomy 21 by maternal age and fetal nuchal-
translucency thickness at 10-14 weeks of gestation. Fetal Medicine Founda-
tion First Trimester Screening Group. Lancet 1998;352:343e6.
[19] Benn PA, Kaminsky LM, Ying J, Borgida AF, Egan JF. Combined second-
trimester biochemical and ultrasound screening for Down syndrome. Obstet
Gynecol 2002;100:1168e76.
[20] Reynolds T. The triple test as a screening technique for Down syndrome:
reliability and relevance. Int J Womens Health 2010;2:83e8.
[21] Debieve F, Bouckaert A, Hubinont C, Thomas K. Multiple screening for fetal
Down's syndrome with the classic triple test, dimeric inhibin A and ultra-
sound. Gynecol Obstet Invest 2000;49:221e6.
[22] Fan HC, Blumenfeld YJ, Chitkara U, Hudgins L, Quake SR. Noninvasive diag-
nosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood.
Proc Natl Acad Sci U S A 2008;105:16266e71.
[23] Hahn S, Lapaire O, Tercanli S, Kolla V, Hosli I. Determination of fetal chro-
mosome aberrations from fetal DNA in maternal blood: has the challenge
ﬁnally been met? Expert Rev Mol Med 2011;13:e16.
[24] Bianchi DW, Lo YM. Fetomaternal cellular and plasma DNA trafﬁcking: the Yin
and the Yang. Ann N Y Acad Sci 2001;945:119e31.
[25] Liao GJ, Gronowski AM, Zhao Z. Non-invasive prenatal testing using cell-free
fetal DNA in maternal circulation. Clin Chim Acta 2014;428:44e50.
[26] Pongsritasana T, Wongratanacheewin S, Prasertcharoensuk V, Sermswan RW.
Isolation of fetal nucleated red blood cell from maternal blood using immu-
nomagnetic beads for prenatal diagnosis. Asian Pac J Allergy Immunol
2006;24:65e71.
[27] Wachtel SS, Shulman LP, Sammons D. Fetal cells in maternal blood. Clin Genet
2001;59:74e9.
[28] Papageorgiou EA, Patsalis PC. Non-invasive prenatal diagnosis of aneu-
ploidies: new technologies and clinical applications. Genome Med 2012;4:46.
[29] Wald NJ, Cuckle HS, Densem JW, Nanchahal K, Royston P, Chard T, et al.
Maternal serum screening for Down's syndrome in early pregnancy. BMJ
1988;297:883e7.
[30] Shaw SW, Lin SY, Lin CH, Su YN, Cheng PJ, Lee CN, et al. Second-trimester
maternal serum quadruple test for Down syndrome screening: a Taiwanese
population-based study. Taiwan J Obstet Gynecol 2010;49:30e4.
[31] Phillips OP, Elias S, Shulman LP, Andersen RN, Morgan CD, Simpson JL.
Maternal serum screening for fetal Down syndrome in women less than 35
years of age using alpha-fetoprotein, hCG, and unconjugated estriol: a pro-
spective 2-year study. Obstet Gynecol 1992;80:353e8.
[32] Chao AS, Chung CL, Wu CD, Chang SD, Cheng PJ, Lin YT, et al. Second trimester
maternal serum screening using alpha fetoprotein, free beta human chorionic
gonadotropin and maternal age speciﬁc risk: result of chromosomal abnor-
malities detected in screen positive for Down syndrome in an Asian popula-
tion. Acta Obstet Gynecol Scand 1999;78:393e7.[33] Hsiao CH, Cheng PJ, Shaw SW, Hsu JJ, Chen RC, Tseng YJ, et al. Extended First-
trimester screening using multiple sonographic markers and maternal serum
biochemistry: A ﬁve-year prospective study. Fetal Diagn Ther 2014;35:
296e301.
[34] Chen XQ, Stroun M, Magnenat JL, Nicod LP, Kurt AM, Lyautey J, et al. Micro-
satellite alterations in plasma DNA of small cell lung cancer patients. Nat Med
1996;2:1033e5.
[35] Nawroz H, Koch W, Anker P, Stroun M, Sidransky D. Microsatellite alterations
in serum DNA of head and neck cancer patients. Nat Med 1996;2:1035e7.
[36] Lo YM, Corbetta N, Chamberlain PF, Rai V, Sargent IL, Redman CW, et al.
Presence of fetal DNA in maternal plasma and serum. Lancet 1997;350:485e7.
[37] Poon LL, Leung TN, Lau TK, Lo YM. Presence of fetal RNA in maternal plasma.
Clin Chem 2000;46:1832e4.
[38] Lo YM, Tein MS, Lau TK, Haines CJ, Leung TN, Poon PM, et al. Quantitative
analysis of fetal DNA in maternal plasma and serum: implications for
noninvasive prenatal diagnosis. Am J Hum Genet 1998;62:768e75.
[39] Saito H, Sekizawa A, Morimoto T, Suzuki M, Yanaihara T. Prenatal DNA diag-
nosis of a single-gene disorder from maternal plasma. Lancet 2000;356:1170.
[40] Chiu RW, Lau TK, Leung TN, Chow KC, Chui DH, Lo YM. Prenatal exclusion of
beta thalassaemia major by examination of maternal plasma. Lancet
2002;360:998e1000.
[41] Vrettou C, Traeger-Synodinos J, Tzetis M, Malamis G, Kanavakis E. Rapid
screening of multiple beta-globin gene mutations by real-time PCR on the
LightCycler: application to carrier screening and prenatal diagnosis of thal-
assemia syndromes. Clin Chem 2003;49:769e76.
[42] Li Y, Di Naro E, Vitucci A, Zimmermann B, Holzgreve W, Hahn S. Detection of
paternally inherited fetal point mutations for beta-thalassemia using size-
fractionated cell-free DNA in maternal plasma. JAMA 2005;293:843e9.
[43] Chan KC, Ding C, Gerovassili A, Yeung SW, Chiu RW, Leung TN, et al. Hyper-
methylated RASSF1A in maternal plasma: A universal fetal DNA marker that
improves the reliability of noninvasive prenatal diagnosis. Clin Chem
2006;52:2211e8.
[44] Lun FM, Chiu RW, Allen Chan KC, Yeung Leung T, Kin Lau T, Dennis Lo YM.
Microﬂuidics digital PCR reveals a higher than expected fraction of fetal DNA
in maternal plasma. Clin Chem 2008;54:1664e72.
[45] Lau TK, Chan MK, Lo PS, Chan HY, Chan WS, Koo TY, et al. Clinical utility of
noninvasive fetal trisomy (NIFTY) testeearly experience. J Matern Fetal
Neonatal Med 2012;25:1856e9.
[46] Ehrich M, Deciu C, Zwiefelhofer T, Tynan JA, Cagasan L, Tim R, et al. Nonin-
vasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood:
a study in a clinical setting. Am J Obstet Gynecol 2011;204. 205.e201e11.
[47] Sehnert AJ, Rhees B, Comstock D, de Feo E, Heilek G, Burke J, et al. Optimal
detection of fetal chromosomal abnormalities by massively parallel DNA
sequencing of cell-free fetal DNA from maternal blood. Clin Chem 2011;57:
1042e9.
[48] Lau TK, Chen F, Pan X, Pooh RK, Jiang F, Li Y, et al. Noninvasive prenatal
diagnosis of common fetal chromosomal aneuploidies by maternal plasma
DNA sequencing. J Matern Fetal Neonatal Med 2012;25:1370e4.
[49] Shaw SW, Hsiao CH, Chen CY, Ren Y, Tian F, Tsai C, et al. Noninvasive prenatal
testing for whole fetal chromosomal aneuploidies: a multicenter prospective
cohort trial in Taiwan. Fetal Diagn Ther 2014;35:13e7.
[50] Jiang F, Ren J, Chen F, Zhou Y, Xie J, Dan S, et al. Noninvasive Fetal Trisomy
(NIFTY) test: an advanced noninvasive prenatal diagnosis methodology for
fetal autosomal and sex chromosomal aneuploidies. BMC Med Genomics
2012;5:57.
[51] Lapaire O, Holzgreve W, Oosterwijk JC, Brinkhaus R, Bianchi DW. Georg
Schmorl on trophoblasts in the maternal circulation. Placenta 2007 Jan;28(1):
1e5.
[52] Huang Z, Fong CY, Gauthaman K, Sukumar P, Choolani M, Bongso A. Novel
approaches to manipulating foetal cells in the maternal circulation for non-
invasive prenatal diagnosis of the unborn child. J Cell Biochem 2011;112:
1475e85.
[53] Sargent IL, Johansen M, Chua S, Redman CW. Clinical experience: isolating
trophoblasts from maternal blood. Ann New Y Acad Sci 1994;731:154e61.
[54] Durrant LG, Martin WL, McDowall KM, Liu DT. Isolation of fetal trophoblasts
and nucleated erythrocytes from the peripheral blood of pregnant women for
prenatal diagnosis of fetal aneuploides. Early Hum Dev 1996;47:S79e83.
[55] Johnson P, Cheng H, Molloy C, Stern C, Slade M. Human trophoblast-speciﬁc
surface antigens identiﬁed using monoclonal antibodies. Am J Reprod
Immunol 1981;1:246e54.
[56] Bertero MT, Camaschella C, Serra A, Bergui L, Caligaris-Cappio F. Circulating
'trophoblast' cells in pregnancy have maternal genetic markers. Prenatal
Diagn 1988;8:585e90.
[57] Henderson KG, Shaw TE, Barrett IJ, Telenius AH, Wilson RD, Kalousek DK.
Distribution of mosaicism in human placentae. Hum Genetics 1996;97:650e4.
[58] Goldberg JD, Wohlferd MM. Incidence and outcome of chromosomal mosai-
cism found at the time of chorionic villus sampling. Am J Obstet Gynecol
1997;176:1349e52. discussion 1352e3.
[59] Walknowska J, Conte FA, Grumbach MM. Practical and theoretical implica-
tions of fetal-maternal lymphocyte transfer. Lancet 1969;1:1119e22.
[60] Johansen JK, Schacke E, Sturup AG. Foeto-maternal transfusion in relation to
delivery. Ugeskr Laeger 1971;133:870e2.
[61] Grosset L, Barrelet V, Odartchenko N. Antenatal fetal sex determination from
maternal blood during early pregnancy. Am J Obstet Gynecol 1974;120:60e3.
W.-L. Cheng et al. / Taiwanese Journal of Obstetrics & Gynecology 54 (2015) 343e349 349[62] Herzenberg LA, Bianchi DW, Schroder J, Cann HM, Iverson GM. Fetal cells in
the blood of pregnant women: detection and enrichment by ﬂuorescence-
activated cell sorting. Proc Natl Acad Sci U S A 1979;76:1453e5.
[63] Bianchi DW, Zickwolf GK, Weil GJ, Sylvester S, DeMaria MA. Male fetal pro-
genitor cells persist in maternal blood for as long as 27 years postpartum. Proc
Natl Acad Sci U S A 1996;93:705e8.
[64] Calabrese G, Baldi M, Fantasia D, Sessa MT, Kalantar M, Holzhauer C, et al.
Detection of chromosomal aneuploidies in fetal cells isolated from maternal
blood using single-chromosome dual-probe FISH analysis. Clin Genet
2012;82:131e9.
[65] D'Souza E, Ghosh K, Colah R. A comparison of the choice of monoclonal an-
tibodies for recovery of fetal cells from maternal blood using FACS for
noninvasive prenatal diagnosis of hemoglobinopathies. Cytometry B Clin
Cytome 2009;76:175e80.
[66] Babochkina T, Mergenthaler S, Lapaire O, Kiefer V, Yura H, Koike K, et al.
Evaluation of a soybean lectin-based method for the enrichment of erythro-
blasts. J Hhistochem Cytochem 2005;53:329e30.
[67] Mohamed H, Turner JN, Caggana M. Biochip for separating fetal cells from
maternal circulation. J Chromatog A 2007;1162:187e92.
[68] Samura O, Sekizawa A, Zhen DK, Falco VM, Bianchi DW. Comparison of fetal
cell recovery from maternal blood using a high density gradient for the initial
separation step: 1.090 versus 1.119 g/mL. Prenatal Diagn 2000;20:281e6.
[69] Ponnusamy S, Mohammed N, Ho SS, Zhang HM, Chan YH, Ng YW, et al. In vivo
model to determine fetal-cell enrichment efﬁciency of novel noninvasive
prenatal diagnosis methods. Prenatal Diagn 2008;28:494e502.
[70] Prieto B, Alonso R, Paz A, Candenas M, Venta R, Ladenson JH, et al. Optimi-
zation of nucleated red blood cell (NRBC) recovery from maternal blood
collected using both layers of a double density gradient. Prenatal Diagn
2001;21:187e93.
[71] Huang R, Barber TA, Schmidt MA, Tompkins RG, Toner M, Bianchi DW, et al.
A microﬂuidics approach for the isolation of nucleated red blood cells (NRBCs)
from the peripheral blood of pregnantwomen. Prenatal Diagno 2008;28:892e9.
[72] Holzgreve W, Ghezzi F, Di Naro E, Ganshirt D, Maymon E, Hahn S. Disturbed
feto-maternal cell trafﬁc in preeclampsia. Obstet Gynecol 1998;91:669e72.
[73] Kavanagh DM, Kersaudy-Kerhoas M, Dhariwal RS, Desmulliez MP. Current
and emerging techniques of fetal cell separation from maternal blood. J
Chromatogr. B Analyt Technol Biomed Life Sci 2010;878:1905e11.
[74] Choolani M, O'Donoghue K, Talbert D, Kumar S, Roberts I, Letsky E, et al.
Characterization of ﬁrst trimester fetal erythroblasts for non-invasive prenatal
diagnosis. Mol Hum Reprod 2003;9:227e35.
[75] Palis J. To condense is not to die. Blood 2005;106:1900.
[76] Spivak JL. The anaemia of cancer: death by a thousand cuts. Nat Rev Cancer
2005;5:543e55.
[77] Brittain T. Molecular aspects of embryonic hemoglobin function. Mol Aspects
Med 2002;23:293e342.
[78] Manning JM, Popowicz AM, Padovan JC, Chait BT, Manning LR. Intrinsic
regulation of hemoglobin expression by variable subunit interface strengths.
FEBS J 2012;279:361e9.
[79] Choolani M, O'Donnell H, Campagnoli C, Kumar S, Roberts I, Bennett PR, et al.
Simultaneous fetal cell identiﬁcation and diagnosis by epsilon-globin chain
immunophenotyping and chromosomal ﬂuorescence in situ hybridization.
Blood 2001;98:554e7.
[80] Sorensen MD, Gonzalez Dosal R, Jensen KB, Christensen B, Kølvraa S,
Jensen UB, et al. Epsilon haemoglobin speciﬁc antibodies with applications in
noninvasive prenatal diagnosis. J Biomed Biotechnol 2009;2009:659219.
[81] Al-Mufti R, Hambley H, Farzaneh F, Nicolaides KH. Fetal and embryonic he-
moglobins in erythroblasts of chromosomally normal and abnormal fetuses at
10-40 weeks of gestation. Haematologica 2000;85:690e3.[82] Ikeya M, Shinya M, Kitagawa M. Basic investigation of the lectin method for
separation and recovery of nucleated red blood cells in maternal blood, and a
study into the frequency of nucleated red blood cells in fetomaternal disor-
ders. Congenit Anom (Kyoyo) 2005;45:26e31.
[83] Jeon YJ, Kwon KH, Kim JW, Pang M-G, Jung SC, Kim YJ. Comparison in the yield
of fetal nucleated red blood cell between the ﬁrst-and second-trimester using
double density gradient centrifugation. Korean J Obstet Gynecol 2010;53:
127e36.
[84] Bischoff FZ, Marquez-Do DA, Martinez DI, Dang D, Horne C, Lewis D, et al.
Intact fetal cell isolation from maternal blood: improved isolation using a
simple whole blood progenitor cell enrichment approach (RosetteSep). Clin
Genet 2003;63:483e9.
[85] Yan J, Guilbault E, Masse J, Bronsard M, DeGrandpre P, Forest JC, et al. Opti-
mization of the ﬂuorescence in situ hybridization (FISH) technique for high
detection efﬁciency of very small proportions of target interphase nuclei. Clin
Genet 2000;58:309e18.
[86] Posel C, Moller K, Frohlich W, Schulz I, Boltze J, Wagner DC. Density gradient
centrifugation compromises bone marrow mononuclear cell yield. PloS One
2012;7:e50293.
[87] Purwosunu Y, Sekizawa A, Koide K, Okazaki S, Farina A, Okai T. Clinical po-
tential for noninvasive prenatal diagnosis through detection of fetal cells in
maternal blood. Taiwan J Obstet Gynecol 2006;45:10e20.
[88] Ganshirt-Ahlert D, Borjesson-Stoll R, Burschyk M, Dohr A, Garritsen HS,
Helmer E, et al. Detection of fetal trisomies 21 and 18 from maternal blood
using triple gradient and magnetic cell sorting. Am J Reprod Immunol Sep-Oct
1993;30:194e201.
[89] Secker-Walker RH, Solomon LJ, Flynn BS, LePage SS, Crammond JE,
Worden JK, et al. Training obstetric and family practice residents to give
smoking cessation advice during prenatal care. Am J Obstet Gynecol
1992;166:1356e63.
[90] Bianchi DW, Flint AF, Pizzimenti MF, Knoll JH, Latt SA. Isolation of fetal DNA
from nucleated erythrocytes in maternal blood. Proc Natl Acad Sci U S A
1990;87:3279e83.
[91] Henri A, Testa U, Tonthat H, Riou J, Titeux M, Vainchenker W, et al. Disap-
pearance of Hb F and i antigen during the ﬁrst year of life. Am J Hematol
1980;9:161e70.
[92] Twu YC, Chen CP, Hsieh CY, Tzeng CH, Sun CF, Wang SH, et al. I branching
formation in erythroid differentiation is regulated by transcription factor C/
EBPalpha. Blood 2007;110:4526e34.
[93] Liu C, Stakenborg T, Peeters S, Lagae L. Cell manipulation with magnetic
particles toward microﬂuidic cytometry. J Appl Phys 2009;105. http://
dx.doi.org/10.1063/1.3116091.
[94] Lee BS, Lee JN, Park JM, Lee JG, Kim S, Cho YK, et al. A fully automated
immunoassay from whole blood on a disc. Lab Chip 2009;9:1548e55.
[95] Chen KC, Lee TP, Pan YC, Chiang CL, Chen CL, Yang YH, et al. Detection of
circulating endothelial cells via a microﬂuidic disk. Clin Chem 2011;57:
586e92.
[96] Autebert J, Coudert B, Bidard FC, Pierga JY, Descroix S, Malaquin L, et al.
Microﬂuidic: an innovative tool for efﬁcient cell sorting. Methods 2012;57:
297e307.
[97] Chen CL, Chen KC, Pan YC, Lee TP, Hsiung LC, Lin CM, et al. Separation and
detection of rare cells in a microﬂuidic disk via negative selection. Lab Chip
2011;11:474e83.
[98] Mavrou A, Kouvidi E, Antsaklis A, Souka A, Kitsiou Tzeli S, Kolialexi A. Iden-
tiﬁcation of nucleated red blood cells in maternal circulation: a second step in
screening for fetal aneuploidies and pregnancy complications. Prenatal Diagn
2007;27:150e3.
